|
Merck And Co Inc 's Total Debt to Equity
MRK's quarterly Total Debt to Equity and Total Debt, Equity growth
Due to net new borrowings of 0.56%, Total Debt to Equity fell to 0.93, above the Merck And Co Inc 's average Total Debt to Equity.
Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 22 other companies have achieved lower Total Debt to Equity than Merck And Co Inc in the IV Quarter 2023. While Total Debt to Equity total ranking has deteriorated compared to the third quarter 2023 from 745 to 796 .
Explain Debt to Equity Ratio?
What is the structure of MRK´s Total Debt?
How valuable is the MRK´s Equity?
Select the Comparisons :
|
|
Select the Ratio:
|
|
MRK Total Debt to Equity |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity Change |
-18.29 % |
-7.24 % |
-10.56 % |
14.53 % |
20.39 % |
Y / Y Total Debt Change |
14.22 % |
14.6 % |
16.57 % |
-3.3 % |
-7.28 % |
Total Debt to Equity MRQ |
0.93 |
0.84 |
0.95 |
0.66 |
0.67 |
MRK's Total
Ranking |
# 796 |
# 745 |
# 1186 |
# 2252 |
# 650 |
Seq. Equity Change |
-8.87 % |
6.6 % |
-17.4 % |
1.84 % |
3.45 % |
Seq. Total Debt Change |
0.56 % |
-5.56 % |
20.05 % |
0.18 % |
0.9 % |
Total Debt to Equity forth quarter 2023 Company Ranking |
Within: |
No. |
Major Pharmaceutical Preparations Industry |
# 23 |
Healthcare Sector |
# 77 |
Overall Market |
# 796 |
Total Debt to Equity Statistics |
High |
Average |
Low |
1.25 |
0.57 |
0.22 |
(Dec 31 2020) |
|
(March 31, 2008) |
Cumulative Merck And Co Inc 's Total Debt to Equity
MRK's Total Debt to Equity for the trailling 12 Months
MRK Total Debt to Equity |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity TTM Growth |
-18.29 % |
-7.24 % |
-10.56 % |
14.53 % |
20.39 % |
Y / Y Total Debt TTM Growth |
14.22 % |
14.6 % |
16.57 % |
-3.3 % |
-7.28 % |
Total Debt to Equity TTM |
0.84 |
0.77 |
0.73 |
0.68 |
0.71 |
Total
Ranking TTM |
# 29
| # 105
| # 2716
| # 185
| # 1963
|
Seq. Equity TTM Growth |
-8.87 % |
6.6 % |
-17.4 % |
1.84 % |
3.45 % |
Seq. Total Debt TTM Growth |
0.56 % |
-5.56 % |
20.05 % |
0.18 % |
0.9 % |
On the trailing twelve months basis Due to the net new borrowings of 0.56% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeTotal Debt to Equity improved to 0.84, above the Merck And Co Inc 's average Total Debt to Equity. Total Debt to Equity is the average cumulative value over the last four quarters.
Among companies in the Major Pharmaceutical Preparations industry 3, during the past 12 months, other companies have achieved lower Total Debt to Equity than Merck And Co Inc . While Total Debt to Equity total ranking has improved so far to 29, from total ranking in previous 12 month period at 105.
Explain Debt to Equity Ratio?
What is the structure of MRK´s Total Debt?
How valuable is the MRK´s Equity?
TTM Total Debt to Equity Company Ranking |
Within: |
No. |
Within the Major Pharmaceutical Preparations Industry |
# 4 |
Healthcare Sector |
# 7 |
Within the Market |
# 29 |
trailing twelve months Total Debt to Equity Statistics |
High |
Average |
Low |
1.12 |
0.49 |
0.03 | (Mar 31 2021) |
|
|
Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry | Total Debt to Equity | Dec 31 2023 MRQ Total Debt | Dec 31 2023 MRQ Equity | Teva Pharmaceutical Industries Limited | 2.44 | $ 19,833.000 Millions | $ 8,126.000 Millions | Amicus Therapeutics inc | 2.42 | $ 387.858 Millions | $ 160.174 Millions | Eli Lilly And Company | 2.32 | $ 25,225.300 Millions | $ 10,863.700 Millions | Arcutis Biotherapeutics Inc | 2.28 | $ 201.799 Millions | $ 88.667 Millions | Blueprint Medicines Corporation | 2.13 | $ 278.011 Millions | $ 130.609 Millions | Travere Therapeutics Inc | 1.88 | $ 377.263 Millions | $ 200.810 Millions | Phibro Animal Health Corporation | 1.75 | $ 474.898 Millions | $ 270.803 Millions | Ionis Pharmaceuticals Inc | 1.68 | $ 648.453 Millions | $ 386.686 Millions | Eyenovia inc | 1.59 | $ 14.287 Millions | $ 8.999 Millions | Jazz Pharmaceuticals Plc | 1.53 | $ 5,712.942 Millions | $ 3,736.997 Millions | G1 Therapeutics Inc | 1.46 | $ 51.557 Millions | $ 35.386 Millions | Xoma Corporation | 1.40 | $ 124.061 Millions | $ 88.721 Millions | Alimera Sciences Inc | 1.40 | $ 64.489 Millions | $ 46.170 Millions | Biovie Inc | 1.36 | $ 10.195 Millions | $ 7.491 Millions | Catalent Inc | 1.36 | $ 5,005.000 Millions | $ 3,687.000 Millions | Bristol myers Squibb Company | 1.35 | $ 39,772.000 Millions | $ 29,485.000 Millions | Emergent Biosolutions Inc | 1.32 | $ 860.200 Millions | $ 649.300 Millions | Zoetis Inc | 1.32 | $ 6,567.000 Millions | $ 4,991.000 Millions | Soligenix inc | 1.29 | $ 3.261 Millions | $ 2.522 Millions | Summit Therapeutics Inc | 1.29 | $ 100.000 Millions | $ 77.692 Millions | Clene Inc | 1.23 | $ 16.521 Millions | $ 13.390 Millions | Lexicon Pharmaceuticals Inc | 1.07 | $ 99.508 Millions | $ 93.110 Millions | Merck and Co Inc | 0.93 | $ 35,055.000 Millions | $ 37,635.000 Millions | Elanco Animal Health Inc | 0.93 | $ 5,774.000 Millions | $ 6,223.000 Millions | Pds Biotechnology Corp | 0.91 | $ 23.673 Millions | $ 26.131 Millions | Viatris Inc | 0.89 | $ 18,131.500 Millions | $ 20,467.400 Millions | Perrigo Company Plc | 0.85 | $ 4,073.400 Millions | $ 4,767.900 Millions | Ocular Therapeutix Inc | 0.82 | $ 74.925 Millions | $ 91.131 Millions | Biofrontera Inc | 0.81 | $ 3.904 Millions | $ 4.793 Millions | Pfizer Inc | 0.81 | $ 71,888.000 Millions | $ 89,288.000 Millions |
|